SAN DIEGO, Jan. 15, 2019 /PRNewswire/ -- Trovagene,
Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics
company, taking a precision cancer medicine approach to develop
drugs that target cell division (mitosis) for the treatment of
leukemias, lymphomas and solid tumor cancers, announced today that
its Special Meeting of Stockholders ("Special Meeting"), scheduled
for Tuesday, January 15, 2019, has
been adjourned. At the meeting, it was deemed that the holders of a
sufficient number of Trovagene's outstanding common stock have not
yet submitted proxies to indicate how their shares should be voted
and additional time was needed to collect the required votes. The
Special Meeting will resume at 9:00 a.m.
PST on February 12, 2019 at
the company's offices located at 11055 Flintkote Avenue,
San Diego, California 92121.
The company will continue to solicit proxies from stockholders
during the period of adjournment. Only stockholders of record
on the record date of December 14,
2018 are entitled and are being requested to vote. No
further action is required by any stockholder who has submitted his
or her proxy card. The company's Board of Directors and
management respectfully request all such holders as of the record
date who have not yet voted their shares to do so by 11:59 p.m. PST
on Monday, February 11, 2019.
How to Vote
For assistance in voting your shares or for general inquiries
please contact our proxy advisor
Kingsdale Advisors
(866) 851-2484 (toll free)
contactus@kingsdaleadvisors.com
About Trovagene, Inc.
Trovagene is a clinical-stage, oncology therapeutics company,
taking a precision medicine approach to develop drugs that target
mitosis (cell division) to treat various types of cancer, including
leukemias, lymphomas and solid tumors. Trovagene has intellectual
property and proprietary technology that enables the Company to
analyze circulating tumor DNA (ctDNA) and clinically actionable
markers to identify patients most likely to respond to specific
cancer therapies. Trovagene plans to continue to vertically
integrate its tumor genomics technology with the development of
targeted cancer therapeutics. For more information, please
visit www.trovageneoncology.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of words
such as "anticipate," "believe," "forecast," "estimated" and
"intend" or other similar terms or expressions that concern
Trovagene's expectations, strategy, plans or intentions. These
forward-looking statements are based on Trovagene's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, our need for
additional financing; our ability to continue as a going concern;
clinical trials involve a lengthy and expensive process with an
uncertain outcome, and results of earlier studies and trials may
not be predictive of future trial results; our clinical trials may
be suspended or discontinued due to unexpected side effects or
other safety risks that could preclude approval of our product
candidates; uncertainties of government or third party payer
reimbursement; dependence on key personnel; limited experience in
marketing and sales; substantial competition; uncertainties of
patent protection and litigation; dependence upon third
parties; our ability to develop tests, kits and systems and the
success of those products; regulatory, financial and business risks
related to our international expansion and risks related to failure
to obtain FDA clearances or approvals and noncompliance with FDA
regulations. There are no guarantees that any of our technology or
products will be utilized or prove to be commercially successful.
Additionally, there are no guarantees that future clinical trials
will be completed or successful or that any precision medicine
therapeutics will receive regulatory approval for any indication or
prove to be commercially successful. Investors should read the
risk factors set forth in Trovagene's Form 10-K for the year
ended December 31, 2017, and other periodic reports filed with
the Securities and Exchange Commission. While the list of
factors presented here is considered representative, no such list
should be considered to be a complete statement of all potential
risks and uncertainties. Unlisted factors may present significant
additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as
of the date hereof, and Trovagene does not undertake any obligation
to update publicly such statements to reflect subsequent events or
circumstances.
Important Information
In connection with the solicitation of proxies, on December 18, 2018, Trovagene, Inc. filed a
definitive proxy statement with the Securities and Exchange
Commission (the "SEC") in connection with the Company's Special
Meeting. TROVAGENE'S STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE
DEFINITIVE PROXY MATERIALS AND ANY OTHER RELEVANT SOLICITATION
MATERIALS FILED BY TROVAGENE WITH THE SEC BEFORE MAKING ANY VOTING
OR INVESTMENT DECISION BECAUSE THESE DOCUMENTS CONTAIN IMPORTANT
INFORMATION. The Company's proxy statement and any other materials
filed by the Company with the SEC can be obtained free of charge at
the SEC's web site at www.sec.gov. The Company's definitive proxy
materials are also available for free from Trovagene at
www.trovagene.com or by writing to Trovagene at 11055
Flintkote Avenue, San Diego,
California 92121, Attention: Investor Relations. The
contents of the websites referenced above are not deemed to be
incorporated by reference into the proxy statement. Trovagene, Inc.
and its directors and executive officers may be deemed to be
participants in the solicitation of proxies from the stockholders
of Trovagene in connection with the Company's Special Meeting of
Stockholders. Information concerning the interests of participants
in the solicitation of proxies is included in the definitive proxy
statement filed by Trovagene with the SEC on December 18, 2018 in connection with its Special
Meeting of Stockholders.
Trovagene Contact:
Vicki
Kelemen
VP, Clinical Development
858-952-7652
vkelemen@trovagene.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/trovagene-announces-adjournment-of-special-meeting-of-stockholders-until-february-12-2019-300778907.html
SOURCE Trovagene, Inc.